DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Department of Defense
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged. Distinctive Features: The FY26 CTRA offers two funding levels: • Funding Level 1 to support smaller, less complex preclinical and/or clinical research. • Funding Level 2 to support larger, more complex preclinical and/or clinical research.
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Next 90 days
Posted
06/17/2026
Closes
2026-09-18
Eligibility
Eligibility
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Program
Funding area
Science and Technology and other Research and Development - ST
Opportunity #
HT942526DMDRPCTRA
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov